USE OF TOCILIZUMAB AND MESENCHYMAL STROMAL CELLS IN THE TREATMENT OF SEVERE COVID-19 - A CASE REPORT

BACKGROUND: Currently, there is no specific treatment for coronavirus disease, and some drugs and cell-based therapy have been tested as alternatives. This work aims to evaluate the effects of the combined use of humanized recombinant monoclonal antibody capable of binding the IL-6 receptor (Tociliz...

Descripción completa

Detalles Bibliográficos
Autores principales: Senegaglia, AC, Rebelatto, CLK, Franck, CL, Lima, JS, Daga, DR, Shigunov, P, Azambuja, AP, Bana, EG, Marsaro, DB, Schaidt, B, Micosky, A, Jamur, VR, Vaz, IM, Schluga, Y, Leite, LMB, Ribeiro, LL, Correa, A, Brofman, PRS
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2021
Materias:
104
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079859/
http://dx.doi.org/10.1016/j.jcyt.2021.02.111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079859/
http://dx.doi.org/10.1016/j.jcyt.2021.02.111

Ejemplares similares